Marja
Marja Heiskala, San Diego, CA US
Patent application number | Description | Published |
---|---|---|
20090305418 | CELL THERAPY METHOD FOR THE TREATMENT OF TUMORS - T cell responses are often diminished in humans with a compromised immune system. We have developed a method to isolate, stimulate and expand naïve cytotoxic T lymphocyte precursors (CTLp) to antigen-specific effectors, capable of lysing tumor cells in vivo. This ex vivo protocol produces fully functional effectors. Artificial antigen presenting cells (AAPCs; | 12-10-2009 |
Marja Hietarinta-Salakari, Turku FI
Patent application number | Description | Published |
---|---|---|
20120067480 | VEHICLE WINTER TYRE AND STUD FOR THE TYRE - A winter tyre is equipped with studs. The number of studs in the tyre is greater than that stated in the amendment, dating 1 Jun. 2009, to the Finnish Ministry of Transport and Communications Decree 408/2003 concerning vehicle tyre studs. The shape of the stud together with the elasticity of the winter tyre rubber compound creates a piercing force of less than 120 N on the stud. The invention also relates to the stud for a tyre, the tip of the stud being resistant to wear and having a cross-section of 1.80-3.14 mm | 03-22-2012 |
Marja Hohti, Helsinki FI
Patent application number | Description | Published |
---|---|---|
20130124272 | METHOD AND SERVER SYSTEM FOR ENHANCED MANAGEMENT OF EVENT-BASED USER REWARDS - Provision of enhanced rewarding schemes. A first server of a first service domain is configured to maintain a reward database for users of a first service domain. A second server of a second service domain is configured to identify event data items of the second service domain from which information is to be forwarded to the first service domain, and derive information from the identified event data items to forwarded data items. The first server is configured to update the reward account of the user in response to event data items generated in response to activities of the user in the first service domain, and in response to forwarded data items received from the second server. | 05-16-2013 |
Marja Ilmen, Helsinki FI
Patent application number | Description | Published |
---|---|---|
20110287505 | GENETICALLY MODIFIED YEAST SPECIES, AND FERMENTATION PROCESSES USING GENETICALLY MODIFIED YEAST - Yeast cells are transformed with an exogenous xylose isomerase gene. Additional genetic modifications enhance the ability of the transformed cells to ferment xylose to ethanol or other desired fermentation products. Those modifications include deletion of non-specific or specific aldose reductase gene(s), deletion of xylitol dehydrogenase gene(s) and/or overexpression of xylulokinase. | 11-24-2011 |
20110287506 | GENETICALLY MODIFIED YEAST SPECIES, AND FERMENTATION PROCESSES USING GENETICALLY MODIFIED YEAST - Yeastcells are transformed with an exogenous xylose isomerase gene. Additional genetic modifications enhance the ability of the transformed cells to ferment xylose to ethanol or other desired fermentation products. Those modifications include deletion of non-specific or specific aldose reductase gene(s), deletion of xylitol dehydrogenase gene(s) and/or overexpression of xylulokinase. | 11-24-2011 |
20120129229 | Yeast Expressing Cellulases for Simultaneous Saccharification and Fermentation Using Cellulose - Host cells, comprising | 05-24-2012 |
20120129230 | Genetically Modified Yeast of the Species Issatchenkia Orientalis and Closely Related Species, and Fermentation Processes Using Same - Cells of the species | 05-24-2012 |
20140080192 | Genetically Modified Yeast Species, and Fermentation Processes Using Genetically Modified Yeast - Yeast cells are transformed with an exogenous xylose isomerase gene. Additional genetic modifications enhance the ability of the transformed cells to ferment xylose to ethanol or other desired fermentation products. Those modifications include deletion of non-specific or specific aldose reductase gene(s), deletion of xylitol dehydrogenase gene(s) and/or overexpression of xylulokinase. | 03-20-2014 |
Marja Jaattela, Copenhagen DK
Patent application number | Description | Published |
---|---|---|
20090203721 | USE OF SIRAMESINE IN THE TREATMENT OF CANCER - The present invention relates to the treatment of cancer. In particular, the invention provides pharmaceutical compositions comprising siramesine for the treatment of cancer. The invention further provides a method of treatment comprising administering siramesine to a patient suffering from cancer. | 08-13-2009 |
Marja Juustila, Liminka FI
Patent application number | Description | Published |
---|---|---|
20090214653 | Bone morphogenetic protein 4 and osteogenic devices and pharmaceutical products containing thereof - The present invention relates to reindeer bone formation inducing protein called bone morphogenetic protein 4 (BMP-4) and nucleotide molecules encoding the proteins and host cells expressing the proteins. The present invention relates also to the use of the BMP-4 for treating disorders related to bone and cartilage formation. Osteogenic devices and pharmaceutical compositions containing the proteins are also disclosed. | 08-27-2009 |
Marja Juustila, Lumijoki FI
Patent application number | Description | Published |
---|---|---|
20100041595 | Bone morphogenetic protein 3 and osteogenic devices and pharmaceutical products containing thereof - The present invention relates to reindeer bone formation inducing protein called bone morphogenetic protein 3c (BMP-3c), nucleotide molecules encoding the protein and host cells expressing the protein. The present invention relates also to the use of said BMP-3c for treating disorders related to bone and cartilage formation. Osteogenic devices and pharmaceutical compositions containing the protein are also disclosed. | 02-18-2010 |
20100143433 | Bone morphogenetic proteins containing a heparin binding site and osteogenic devices and pharmaceutical products containing thereof - The present invention relates to reindeer bone formation inducing protein called bone morphogenetic protein (BMP), such as BMP-6, containing a heparin binding site and nucleotide molecules encoding the proteins and host cells expressing the proteins. The present invention relates also to the use of the bone morphogenetic protein for treating disorders related to bone and cartilage formation. The present invention further relates to osteogenic devices and pharmaceutical compositions containing the protein. | 06-10-2010 |
Marja Karkkaine, Oulu FI
Patent application number | Description | Published |
---|---|---|
20090199539 | COATING FOR PARTICULATE FILTERS - The invention relates to the coating of a particulate filter used in the treatment of exhaust or waste gases. In the manufacturing of the coating according to the invention, there is used a liquid-based sol, where the average particle size of the contained particles is below 100 nm, preferably below 50 nm. | 08-13-2009 |
Marja Matinmikko, Vtt FI
Patent application number | Description | Published |
---|---|---|
20130072130 | METHOD AND ARRANGEMENT FOR ADAPTIVE SIGNAL DETECTION - The present invention describes a new distributed decision making scheme for adaptive signal detection. The innovation describes an adaptive system and method for allocating signal detection resources that are used to find out the status of channel use (occupied/unoccupied). The system includes selection of suitable spectrum sensing methods and decision combining techniques as well as the associated parameters to meet the requirements set for the system in the specific operational environment. The result is that the system has good performance, simple implementation and is applicable to versatile time-variant situations. | 03-21-2013 |
Marja Riekkola-Vanhanen, Pori FI
Patent application number | Description | Published |
---|---|---|
20080241024 | Method for Leaching Metal Sulphide Minerals - The invention relates to a method for the sulphate-based leaching of metal sulphide minerals, such as chalcopyrite, CuFeS | 10-02-2008 |
Marja Salmimaa, Tampere FI
Patent application number | Description | Published |
---|---|---|
20100277803 | Display Device Having Two Operating Modes - A display device ( | 11-04-2010 |
Marja Sodervall, Ouiu FI
Patent application number | Description | Published |
---|---|---|
20110015448 | METHOD FOR THE PREPARATION OF THERAPEUTICALLY VALUABLE TRIPHENYLBUTENE DERIVATIVES - The present invention concerns a method for the preparation of therapeutically valuable triphenylbutene derivatives, especially ospemifene or fispemifene. | 01-20-2011 |
Marja Sodervall, Oulu FI
Patent application number | Description | Published |
---|---|---|
20080207956 | METHOD FOR THE PREPARATION OF THERAPEUTICALLY VALUABLE TRIPHENYLBUTENE DERIVATIVES - The present invention concerns a method for the preparation of therapeutically valuable triphenylbutene derivatives, especially ospemifene or fispemifene. | 08-28-2008 |
20080214860 | METHODS FOR THE PREPARATION OF FISPEMIFENE FROM OSPEMIFENE - The present invention concerns a method for preparation of fispemifene by use of ospemifene as a starting material. | 09-04-2008 |
Marja Steenman, Nantes Cedex FR
Patent application number | Description | Published |
---|---|---|
20110257140 | Biomarkers of Mineralocorticoid Receptor Activation - The present invention relates to the use of Neutrophil Gelatinase-Associated Lipocalin (NGAL) and/or SERPINA3 as biomarkers of the Mineralocorticoid Receptor (MR) activation in a patient. More particularly, the present invention relates to a method for predicting the responsiveness of a patient to a treatment with a MR antagonist or an aldosterone synthase inhibitor, said method comprising determining in a biological sample obtained from said patient the expression level of the NGAL gene and/or of the SERPINA3 gene. | 10-20-2011 |
Marja Tahtinen, Tampere FI
Patent application number | Description | Published |
---|---|---|
20090252707 | NOVEL EXPRESSION VECTORS AND USES THEREOF - A method for treating an HIV disease in a subject in need of said treatment, comprising administering to the subject a therapeutically effective amount of a DNA vaccine comprising an expression vector and a pharmaceutically acceptable excipient, where the expression vector comprises: (a) a heterologous promoter operatively linked to a DNA sequence encoding a nuclear-anchoring protein, where the nuclear-anchoring protein comprises: (i) a DNA binding domain which binds to a specific DNA binding sequence, and (ii) a functional domain of the Bovine Papilloma Virus Type 1 E2 protein, where the functional domain binds to a nuclear component; (b) a multimerized DNA sequence that forms a binding site for the nuclear anchoring protein; and (c) at least one expression cassette comprising a DNA sequence encoding a protein or peptide that stimulates an immune response specific to the protein or peptide; where the expression vector lacks an origin of replication functional in mammalian cells. | 10-08-2009 |
20140234361 | NOVEL EXPRESSION VECTORS AND USES THEREOF - A method for treating an HIV disease in a subject in need of said treatment, comprising administering to the subject a therapeutically effective amount of a DNA vaccine comprising an expression vector and a pharmaceutically acceptable excipient, where the expression vector comprises: (a) a heterologous promoter operatively linked to a DNA sequence encoding a nuclear-anchoring protein, where the nuclear-anchoring protein comprises: (i) a DNA binding domain which binds to a specific DNA binding sequence, and (ii) a functional domain of the Bovine Papilloma Virus Type 1 E2 protein, where the functional domain binds to a nuclear component; (b) a multimerized DNA sequence that forms a binding site for the nuclear anchoring protein; and (c) at least one expression cassette comprising a DNA sequence encoding a protein or peptide that stimulates an immune response specific to the protein or peptide; where the expression vector lacks an origin of replication functional in mammalian cells. | 08-21-2014 |
Marja Tiita, Porvoo FI
Patent application number | Description | Published |
---|---|---|
20110087058 | DEOXYGENATION OF MATERIALS OF BIOLOGICAL ORIGIN - The present invention relates to a method for the deoxygenation of materials of biological origin and particularly to the removal of oxygen from biomass derived organic compounds with carbon monoxide, to yield linear and branched hydrocarbons suitable as biofuels or as blending stocks or components for biofuels, such as gas, gasoline, diesel fuel and aviation fuel, as well as solvents. The method comprises contacting a feedstock with carbon monoxide in the presence of a catalyst comprising a metal selected from a group consisting of ruthenium, manganese, rhodium, rhenium, osmium, iridium, molybdenum, copper, zinc, palladium, platinum and cobalt, in the presence of water, under alkaline conditions at a temperature from 150 to 350° C. and under a pressure from 0.1 to 150 bar, to produce hydrocarbons. | 04-14-2011 |
20110230690 | PROCESS FOR OLIGOMERIZING OLEFINS - A process for oligomerizing olefinic, lower hydrocarbons. The process comprises the steps of feeding a fresh olefinic hydrocarbon feedstock to a reaction zone; contacting the olefinic hydrocarbons of the feedstock with an acidic catalyst in the reaction zone in order to dimerize at least a part of the olefinic hydrocarbons, withdrawing an effluent containing oligomerized olefins from the reaction zone; and conducting the effluent to a separation zone, wherein the oligomerization reaction product is separated from said effluent. According to the invention, the reaction is carried out in homogeneous phase comprising a solvent for olefinic hydrocarbons, maintained at supercritical conditions. By using supercritical carbon dioxide as a solvent deactivation rate of catalyst can be diminished. Carbon dioxide is easy to remove from the product mixture and spent reaction medium can be used for regeneration of the catalyst. | 09-22-2011 |
Marja Tiitta, Porvoo FI
Patent application number | Description | Published |
---|---|---|
20090270245 | CATALYTIC MATERIALS AND METHOD FOR THE PREPARATION THEREOF - The invention is related to catalytic materials and particularly to mesoporous molecular sieves embedded with a zeolite, which are thermally stable at a temperature of at least 900° C., and to a method for the preparation of the catalytic materials. Said catalytic materials are suitable for applications in the field of hydrocarbon processing. | 10-29-2009 |
20100298616 | METHOD FOR THE MANUFACTURE OF BRANCHED SATURATED HYDROCARBONS - The invention relates to a method for the manufacture of branched saturated hydrocarbons, said method comprising the steps where a feed comprising olefins having at least 10 carbons is simultaneously hydrogenated and isomerized in the presence of hydrogen at a temperature of 100-400° C., under hydrogen partial pressure of 0.01-10 MPa, in the presence of a catalyst comprising a metal selected from the metals of Group VIIIb of the Periodic table of Elements, a molecular sieve selected from ten member ring molecular sieves, twelve member ring molecular sieves and mesoporous molecular sieves embedded with zeolite, and a carrier, to yield branched saturated hydrocarbons. | 11-25-2010 |
20130005838 | METHOD FOR ADJUSTING HYDROGEN TO CARBON MONOXIDE RATIO IN SYNTHESIS GAS - A method for adjusting hydrogen to carbon monoxide ratio of syngas contaminated by sulfur impurities involving a water gas shift (WGS) reaction. In light of the presence of the sulfur impurities, the WGS can be implemented as a sour gas shift. WGS can provide good results by using a non-sulfided catalyst. Conditions can be employed which contribute to further enhanced CO-conversion in the reaction. The hydrocarbons or derivatives thereof obtainable from the method can further be refined and used for production of fuels or lubricants for combustion engines. | 01-03-2013 |
20130053456 | TWO-STAGE GAS WASHING METHOD APPLYING SULFIDE PRECIPITATION AND ALKALINE ABSORPTION - Disclosed is a method relating to hydrocarbon production by gasification of carbonaceous material, for example, a two-stage gas washing method as a part of gas refining. Disclosed is a method for hydrogen sulfide and carbon dioxide removal from synthesis gas produced by gasification. Disclosed is a use of a combination of two chemical wash approaches. The process can be utilized as a part of biomass to liquid (BTL) process. | 02-28-2013 |
20130053457 | METHOD FOR NAPHTHALENE REMOVAL - A method for naphthalene removal from a gas using a solid adsorbent material including benzene for the removal. The removal can be applied to, for example, a crude syngas main stream and/or a carbon dioxide exhaust side stream. The adsorption to the adsorbent material can be reversible so that the material can be reused and naphthalene and possibly benzene can be recovered after regeneration. | 02-28-2013 |
Marja Van Meijer, Amsterdam NL
Patent application number | Description | Published |
---|---|---|
20100184671 | Binding molecules for the treatment of myeloid cell malignancies - Provided is a human C-type lectin, binding molecules that specifically bind to the human C-type lectin, nucleic acid molecules encoding the binding molecules or the human C-type lectin, compositions comprising the binding molecules or the human C-type lectin and methods of identifying or producing the binding molecules. The human C-type lectin is specifically expressed on myeloid cells and binding molecules capable of specifically binding to the human C-type lectin can be used in the diagnosis, prevention and/or treatment of neoplastic disorders and diseases. | 07-22-2010 |
20120270802 | BINDING MOLECULES FOR THE TREATMENT OF MYELOID CELL MALIGNANCIES - Provided is a human C-type lectin, binding molecules that specifically bind to the human C-type lectin, nucleic acid molecules encoding the binding molecules or the human C-type lectin, compositions comprising the binding molecules or the human C-type lectin and methods of identifying or producing the binding molecules. The human C-type lectin is specifically expressed on myeloid cells and binding molecules capable of specifically binding to the human C-type lectin can be used in the diagnosis, prevention, and/or treatment of neoplastic disorders and diseases. | 10-25-2012 |